Ipsal L Inhaler is a combination bronchodilator containing Levosalbutamol 50 mcg and Ipratropium 20 mcg per actuation, indicated for the management of chronic obstructive pulmonary disease (COPD) and asthma requiring dual bronchodilation. Levosalbutamol, a selective β2-adrenergic receptor agonist, provides rapid relief of bronchospasm by relaxing airway smooth muscle, thereby improving airflow and reducing symptoms such as wheezing and shortness of breath. Ipratropium, an anticholinergic agent, complements this effect by inhibiting muscarinic receptors in the airway, leading to sustained bronchodilation through reduced vagal tone. The combined action of these agents results in enhanced bronchodilation compared to monotherapy, improving lung function and exercise tolerance. Ipsal L Inhaler is administered via metered-dose inhalation, allowing for targeted delivery to the respiratory tract with minimal systemic absorption. It is recommended for patients inadequately controlled on single bronchodilator therapy or those experiencing frequent exacerbations. Common adverse effects may include dry mouth, tremor, headache, and palpitations. Use with caution in patients with cardiovascular disorders, glaucoma, or prostatic hypertrophy. Regular monitoring of respiratory status and adherence to prescribed dosing is essential to optimize therapeutic outcomes.